Glenmark gains at Fulford’s cost - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark gains at Fulford’s cost

May 16, 2000

The dermatology segment (which deals with skin infections) of the pharmaceutical formulation industry has been witnessing a heavy dose of competition. While the overall formulation segment has grown at 9.8% for FY2000, this segment has grown at only 8.2%. While the market leader Glaxo seems to have slightly increased its market share, a relatively smaller company, Glenmark Pharmaceuticals seems to be a major gainer at the cost of its bigger rivals Fulford and Ranbaxy. This seems to be primarily due to the marketing push the company has been given to its products particularly Candid, its dermatological brand which seems to be following in Glaxo’s footsteps.

As per the ORG data (see table) Glaxo remains the market leader by far, with a 16.9% market share in the dermatology segment. This is due to the fact that its Betnovate range of formulations have achieved near OTC status (Over the Counter) despite being prescription brands.

  Value (Rs m) Market Share Growth
Overall Value 7,549 100.0% 8.2%
Glaxo–Wellcome 1,278 16.9% 8.9%
Fulford 649 8.6% -7.3%
Ranbaxy–Croslands 471 6.2% 3.0%
Glenmark Pharma 434 5.8% 26.2%

Source ORG RSA Mar 2000

The surprise has however been an over 25% growth for Candid. Though one can argue that Glenmark’s growth has been from a much lower base (since Glaxo’s dermatological revenues almost equal the entire revenues of the Glenmark) this just shows the importance of brand building and establishing mind recall for pharma products and the benefits it yields during a slowdown in the industry.

Equitymaster requests your view! Post a comment on "Glenmark gains at Fulford’s cost". Click here!

  

More Views on News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 3, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS